Brand Name

Columvi

Generic Name
Glofitamab
View Brand Information
FDA approval date: June 15, 2023
Classification: Bispecific CD20-directed CD3 T Cell Engager
Form: Concentrate, Solution

What is Columvi (Glofitamab)?

COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (1.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as oth...

A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated With CD19-Directed CAR T-Cell Therapy
A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated With CD19-Directed CAR T-Cell Therapy
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Biological, Procedure
Study Phase: Phase 2

Summary: This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory) after receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is a form of immunotherapy ...

A Phase 2 Study Evaluating the Bispecific CD3xCD20 Antibody GLOfitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) in Patients With RIchter Syndrome as Frontline therapY. A FILO Study
A Phase 2 Study Evaluating the Bispecific CD3xCD20 Antibody GLOfitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) in Patients With RIchter Syndrome as Frontline therapY. A FILO Study
Enrollment Status: Recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: This is a national clinical trial, multicentric (28 centers), non-randomized phase 2 study. Population: Patients with previously untreated Richter's syndrome (RS), defined as the occurrence of an aggressive lymphoma (of diffuse large B-cell lymphoma histology) in a patient with chronic lymphocytic leukemia (CLL). Study treatment: The duration of each cycle is 21 days. Cycle 1: Participants will re...

View All Clinical Trials

Related Latest Advances

Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.
Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.
Journal: Expert opinion on biological therapy
Published: December 12, 2025
Current progress and latest therapeutic options in immuno-oncology
Current progress and latest therapeutic options in immuno-oncology
Journal: Deutsche medizinische Wochenschrift (1946)
Published: October 28, 2025
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US.
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US.
Journal: Future oncology (London, England)
Published: October 21, 2025
View All Latest Advances

Brand Information

Columvi (Glofitamab)
WARNING: CYTOKINE RELEASE SYNDROME
Cytokine Release Syndrome (CRS), including serious or fatal reactions, can occur in patients receiving COLUMVI. Premedicate before each dose, and initiate treatment with the COLUMVI step-up dosing schedule to reduce the risk of CRS. Withhold COLUMVI until CRS resolves or permanently discontinue based on severity [see .
1INDICATIONS AND USAGE
COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate and durability of response
2DOSAGE FORMS AND STRENGTHS
Injection:
  • 2.5 mg/2.5 mL (1 mg/mL) clear, colorless solution in a single-dose vial.
  • 10 mg/10 mL (1 mg/mL) clear, colorless solution in a single-dose vial.
3CONTRAINDICATIONS
None.
4ADVERSE REACTIONS
The following clinically significant adverse reactions are described elsewhere in the labeling:
  • Cytokine Release Syndrome
  • Neurologic Toxicity
  • Serious Infections
  • Tumor Flare
4.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
5DRUG INTERACTIONS
For certain CYP substrates where minimal concentration changes may lead to serious adverse reactions, monitor for toxicities or drug concentrations of such CYP substrates when coadministered with COLUMVI.
Glofitamab-gxbm causes the release of cytokines
6DESCRIPTION
Glofitamab-gxbm is a bispecific CD20-directed CD3 T-cell engager. It is a recombinant humanized anti-CD20 anti-CD3ɛ bispecific immunoglobulin G1 (IgG1) monoclonal antibody produced in Chinese hamster ovary (CHO) cells. Glofitamab-gxbm has an approximate molecular weight of 197 kDa.
COLUMVI (glofitamab-gxbm) injection is a sterile, preservative-free, colorless, clear solution supplied in single-dose vials for intravenous infusion.
COLUMVI is supplied in 2.5 mg/2.5 mL and 10 mg/10 mL single-dose vials at a concentration of 1 mg/mL. Each mL of solution contains 1 mg glofitamab-gxbm, histidine (0.63 mg), histidine hydrochloride monohydrate (3.34 mg), methionine (1.49 mg), polysorbate 20 (0.5 mg), sucrose (82.15 mg), and Water for Injection, USP, at pH 5.5.
7HOW SUPPLIED/STORAGE AND HANDLING
COLUMVI (glofitamab-gxbm) injection is a sterile, preservative-free, colorless, clear solution for intravenous infusion.
COLUMVI is supplied as:
8PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (
9PRINCIPAL DISPLAY PANEL - 10 mg/10 mL Vial Carton
NDC 50242-127-01
Columvi
(glofitamab-gxbm)
10 mg/10 mL
For Intravenous Infusion
Single-Dose Vial.
ATTENTION: Dispense the enclosed
1 vial
Rx only
11038205
PRINCIPAL DISPLAY PANEL - 10 mg/10 mL Vial Carton
10PRINCIPAL DISPLAY PANEL - 2.5 mg/2.5 mL Vial Carton
NDC 50242-125-01
Columvi
(glofitamab-gxbm)
2.5 mg/2.5 mL
For Intravenous Infusion
Single-Dose Vial.
ATTENTION: Dispense the enclosed
1 vial
Rx only
11038250
PRINCIPAL DISPLAY PANEL - 2.5 mg/2.5 mL Vial Carton